A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.

Trial Profile

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2011

At a glance

  • Drugs Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms Nordic-VI
  • Most Recent Events

    • 25 Jun 2011 Quality of life results presented at the 13th World Congress on Gastrointestinal Cancer.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top